NCT07191873 - Tirzepatide in Idiopathic Intracranial Hypertension Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

September 30, 2027

Conditions

Idiopathic Intracranial Hypertension (IIH)

Interventions

DRUG

Tirzepatide

Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months

DRUG

Tirzepatide Placebo

Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months

Trial Locations (1)

Duke University Medical Center, Durham